ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
125.016,41
-0,52%
S&P 500
5.998,74
0,00%
US Dollar vs BRL
6,0575
1,39%
Bitcoin
95.709,09
-1,60%
Brent Oil
72,755
0,94%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. ImmunoGen Inc (IMGN)

  7. ImmunoGen Inc (IMGN) Notícias

IMGN

ImmunoGen (IMGN)

ImmunoGen Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:IMGN
DataHoraFonteTítuloCódigoCompanhia
22/02/202418:15Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:IMGNImmunoGen Inc
14/02/202419:01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IMGNImmunoGen Inc
12/02/202418:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMGNImmunoGen Inc
12/02/202418:33Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:IMGNImmunoGen Inc
12/02/202411:32Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:IMGNImmunoGen Inc
12/02/202409:52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMGNImmunoGen Inc
12/02/202409:37PR Newswire (US)AbbVie Completes Acquisition of ImmunoGenNASDAQ:IMGNImmunoGen Inc
05/02/202418:10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IMGNImmunoGen Inc
01/02/202418:30Business WireImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IMGNImmunoGen Inc
29/01/202419:01Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:IMGNImmunoGen Inc
12/01/202413:10PR Newswire (US)Kuehn Law Encourages PXD, IMGN, HA and ICVX Investors to Contact Law FirmNASDAQ:IMGNImmunoGen Inc
02/01/202420:10PR Newswire (US)Kuehn Law Encourages CERE, HA, IMGN, and WAVD Investors to Contact Law FirmNASDAQ:IMGNImmunoGen Inc
02/01/202418:26Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:IMGNImmunoGen Inc
21/12/202318:52Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:IMGNImmunoGen Inc
19/12/202321:00Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:IMGNImmunoGen Inc
10/12/202314:00Business WireImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASHNASDAQ:IMGNImmunoGen Inc
08/12/202308:23IH Market NewsApple Boosts Vietnam Production, Broadcom Revenue Miss, Stellantis Job Cuts – Latest UpdatesNASDAQ:IMGNImmunoGen Inc
05/12/202309:46Dow Jones NewsImmunogen Gets FDA Priority Review of Elahere Full ApprovalNASDAQ:IMGNImmunoGen Inc
30/11/202310:42Dow Jones NewsImmunoGen Shares Soar Premarket on Takeover by AbbVieNASDAQ:IMGNImmunoGen Inc
30/11/202310:13Dow Jones NewsAbbVie to Buy ImmunoGen for More Than $10 BillionNASDAQ:IMGNImmunoGen Inc
30/11/202309:30PR Newswire (US)AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor PortfolioNASDAQ:IMGNImmunoGen Inc
02/11/202317:30Business WireImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare ConferenceNASDAQ:IMGNImmunoGen Inc
02/11/202317:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMGNImmunoGen Inc
02/11/202307:30Business WireImmunoGen Reports Recent Progress and Third Quarter 2023 Financial ResultsNASDAQ:IMGNImmunoGen Inc
27/10/202307:30Business WireImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian CancerNASDAQ:IMGNImmunoGen Inc
23/10/202309:30PR Newswire (US)Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory BoardNASDAQ:IMGNImmunoGen Inc
19/10/202317:01Business WireImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating ResultsNASDAQ:IMGNImmunoGen Inc
28/09/202308:00Business WireELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian CancerNASDAQ:IMGNImmunoGen Inc
19/09/202318:37Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMGNImmunoGen Inc
18/09/202307:30Business WireImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial OfficerNASDAQ:IMGNImmunoGen Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:IMGN

Seu Histórico Recente

BOV
ATOM3
ATOMPAR ON
BOV
IBOV
Índice Bovespa
BOV
AZEV4
AZEVEDO PN
BOV
BHIA3
Grupo Casas Bahia ON
BOV
HAGA3
HAGA ON
BOV
TELB4
TELEBRAS PN
BOV
AGXY3
Agrogalaxy Participacoes ON
BOV
RNEW4
RENOVA PN
BOV
PMAM3
PARANAPANEMA ON
BOV
LUPA3
LUPATECH ON
BOV
IDIV
Dividend
BOV
BRFS3
BRF S/A ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Economize até 50%* para TRADER BRASIL

1 ano 30%, 2 anos 40% e *3 anos 50%

*Ao longo de 3 anos $ 881.64 apenas $ 440.82